Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Boys aged 12 and 13 years to be offered HPV vaccine from September 2019, PHE announces

Boy having HPV vaccine


Mary Ramsay, head of immunisation at Public Health England, said the universal vaccination programme will help build on the success of the girls’ programme

From September 2019, boys aged 12 and 13 years will be offered the free human papillomavirus (HPV) vaccine, Public Health England (PHE) has announced.

Researchers estimate that the HPV vaccine programme will lead to the prevention of over 64,000 cervical cancers and nearly 50,000 non-cervical cancers, including cancers of the head and neck, and genital cancers, by 2058.

Mary Ramsay, head of immunisation at PHE, said: “This universal programme offers us the opportunity to make HPV-related diseases a thing of the past and build on the success of the girls’ programme.

“I encourage all parents of eligible boys and girls to make sure they take up the offer for this potentially life-saving vaccine. It’s important not to delay vaccination, as the vaccine may be less effective as adolescents get older.”

Dame Parveen Kumar, chair of the British Medical Association’s board of science, described the announcement as “a very important step”.

“Universal HPV vaccination is the most effective way of preventing HPV-related infection and disease … given the growing body of evidence that HPV is also responsible for a range of cancers that can affect men.”

In July 2018, the government’s Joint Committee on Vaccination and Immunisations made the recommendation that boys aged 12 and 13 years should be given the HPV vaccination as part of a gender-neutral programme.

This recommendation contradicted interim advice issued in July 2017 which concluded that offering the vaccine to boys would not be cost effective.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206777

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.